Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting
Authors:
- 14 February 2023
- journal article
- review article
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 38 (4-6) , 352-370
Abstract
Significance: Cancer is frequently associated with the early appearance of cachexia, a multifactorial wasting syndrome. If not present at diagnosis, cachexia develops either as a result of tumor progression or as a side effect of anticancer treatments, especially of standard chemotherapy, eventually representing the direct cause of death in up to one-third of all cancer patients. Cachexia, within its multiorgan affection, is characterized by severe loss of muscle mass and function, representing the most relevant subject of preclinical and clinical investigation. Recent Advances: The pathogenesis of muscle wasting in cancer- and chemotherapy-induced cachexia is complex, and encompasses heightened protein catabolism and reduced anabolism, disrupted mitochondria and energy metabolism, and even neuromuscular junction dismantling. The mechanisms underlying these alterations are still controversial, especially concerning the molecular drivers that could be targeted for anticachexia therapies. Inflammation and mitochondrial oxidative stress are among the principal candidates; the latter being extensively discussed in the present review. Critical Issues: Several approaches have been tested to modulate the redox homeostasis in tumor hosts, and to counteract cancer- and chemotherapy-induced muscle wasting, from exercise training to distinct classes of direct or indirect antioxidants. We herein report the most relevant results obtained from both preclinical and clinical trials. Future Directions: Including the assessment and the treatment of altered redox balance in the clinical management of cancer patients is still a big challenge. The available evidence suggests that fortifying the antioxidant defenses by either pharmacological or nonpharmacological strategies will likely improve cachexia and eventually the outcome of a broad cancer patient population. Antioxid. Redox Signal. 38, 352–370.Keywords
This publication has 195 references indexed in Scilit:
- Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathwaysAGE, 2012
- Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancyThe Lancet, 2012
- Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscleJournal of Cachexia, Sarcopenia and Muscle, 2011
- Oral Resveratrol Therapy Inhibits Cancer-Induced Skeletal Muscle and Cardiac Atrophy In VivoNutrition and Cancer, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumabMedical Oncology, 2011
- Increased superoxide in vivo accelerates age‐associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degenerationThe FASEB Journal, 2009
- Taxane pathwayPharmacogenetics and Genomics, 2009
- Hydrogen peroxide impairs insulin-stimulated assembly of mTORC1Free Radical Biology and Medicine, 2009
- PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcriptionProceedings of the National Academy of Sciences, 2006